Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.

NCT00500539 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: omalizumab

Sponsor

Novartis

Collaborators

[object Object]
[object Object]